Skip to main content
. 2012 Apr 18;2012(4):CD007101. doi: 10.1002/14651858.CD007101.pub2

Pappone 2006.

Methods Randomised controlled trial.
Participants Included patients with: Age >18 or<70 years; Creatinine concentration <1.5 mg/dl; AF history > 6 months; AF burden > 2 episodes/month in the last 6 months. 198 patients were included. 99 were arranged to CPVA group, and 99 to ADT group.
Age: 55+/‐10 years in CPVA group, and 57+/‐10 years in ADT group. 
 % of male: 69/99 (70%) in CPVA group, and 64/99 (65%) in ADT group. 
 Follow‐up: 12 months.
Location: Milan, Italy.
Interventions Ablation group: Circumferential pulmonary vein ablation.
ADT group: amiodarone, flecainide, or sotalol, either as single drugs or in combination, at the maximum tolerable doses.
Outcomes Freedom from documented recurrent atrial tachycardia.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Insufficient detail was provided.
Allocation concealment (selection bias) Unclear risk B‐Unclear. The authors did not depict allocation concealment method.
Blinding High risk Blinding was not reported.
Incomplete outcome data addressed High risk There were no patients withdrawn or lost to follow up.
Adequate sequence generation Unclear risk It was not addressed.